September 19, 2011
Merck Serono announced on September 7 that Korosho has completed a review of the results of all-case post-marketing surveillance (PMS) for the anticancer agent Erbitux (cetuximab) and notified the company on September 1 that all-case PMS may be terminated. All-case...read more